A5047945816- Menopause: Health Impacts and Treatments
- Estrogen and related hormone effects
- Sexual function and dysfunction studies
- COVID-19 Impact on Reproduction
- Health disparities and outcomes
- Reproductive Health and Contraception
- Vaccine Coverage and Hesitancy
- Ectopic Pregnancy Diagnosis and Management
- Menstrual Health and Disorders
- Gynecological conditions and treatments
- Phytoestrogen effects and research
- Treatment of Major Depression
- Maternal and Perinatal Health Interventions
- Sexuality, Behavior, and Technology
- Blood disorders and treatments
- Pelvic floor disorders treatments
- Demographic Trends and Gender Preferences
- Chronic Lymphocytic Leukemia Research
- Cardiac Health and Mental Health
- Blood Pressure and Hypertension Studies
- Climate Change and Health Impacts
- Maternal and fetal healthcare
- Psoriasis: Treatment and Pathogenesis
- Immunodeficiency and Autoimmune Disorders
- Eating Disorders and Behaviors
Johnson & Johnson (United States)
2022-2023
Seattle University
2023
Gates Foundation
2023
Bayer (United States)
2015-2017
Ziekenhuis Rivierenland
2016
Pfizer (United States)
2011-2012
Johnson University
2007
Objective The aim of this study was to assess the 12-week efficacy desvenlafaxine in treating moderate severe vasomotor symptoms and clinical relevance improvements postmenopausal women experiencing 50 or more hot flashes per week. Methods Participants were randomized placebo 100 mg/day substudy a year-long, multicenter, parallel-group, double-blind study. Coprimary outcomes changes from baseline daily number severity on weeks 4 12. percentage achieving minimal clinically important...
To evaluate the efficacy and safety of desvenlafaxine (administered as succinate) vs. tibolone placebo for menopausal vasomotor symptoms incidence uterine bleeding.This 12-week, double-blind, randomized, controlled trial was conducted at 35 sites in Europe, two South Africa, one site Mexico. Postmenopausal women with ≥50 moderate or severe hot flushes per week (n = 485) were randomized to 100 mg/day, 2.5 placebo. Reduction average daily number weeks 4 12 (primary endpoint) evaluated using...
Article Abstract Objective: To assess short-term efficacy and safety of desvenlafaxine 50 100 mg/d versus placebo for treating major depressive disorder (MDD). Assessment sexual function was a secondary objective. Method: Outpatients (≥ 18 years) who met criteria MDD from the Diagnostic Statistical Manual Mental Disorders, Fourth Edition, Text Revision had screening baseline 17-item Hamilton Depression Rating Scale (HDRS17) total scores ≥ 20 were randomly assigned to or in an 8-week study...
The purpose of this study was to assess the 1-year maintenance efficacy desvenlafaxine 100 mg/day (administered as succinate) established on week 12 in a 1-year, double-blind, randomized, placebo-controlled trial postmenopausal women seeking treatment bothersome vasomotor symptoms.Primary endpoints were changes hot flush (HF) frequency and severity weeks 12, 26, 52 an substudy population (≥50 moderate severe HFs per at baseline). Secondary Greene climacteric scale, patient global impression...
Nearly all (94%-99%) pregnant persons in developed countries search for pregnancy-related information online. The advent of the novel coronavirus disease 2019 (COVID-19) and associated restrictions hospital policies may have pushed United States to consider giving birth at home achieve their desired experience.Google Trends is an open, rich source real-time, anonymized, relative data on patterns population behavior that provides form volume index (SVI): a queried term overall given time...
The United States maternal mortality (MM) rate is the highest amid developed/industrialized nations, and New Jersey's among highest. Healthcare professionals, public health officials, policy makers are working to understand drivers of MM. An interactive data visualization tool for MM health-related information (New Jersey Maternal Mortality Dashboard [NJMMD]) was recently developed.NJMMD an open-source application that uses from publicly available state/federal government sources provide a...
Abstract We carry out an analysis of gender differences in patterns disease diagnosis across four large observational health datasets and find that women are routinely older when first assigned most diagnoses. Among 112 acute chronic diseases, experience longer lengths time between symptom onset than men for diseases regardless metric used, even only symptoms common to both genders considered. These findings consistent patients with private as well government insurance. Our highlights...
A previous trial of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine (administered as succinate) raised concerns on potential serious cardiovascular and hepatic events. The current study was designed to estimate these events in versus placebo a larger population followed for 1 year.Healthy postmenopausal women seeking treatment vasomotor symptoms were randomized or 100 mg/day 1-year, multicenter, double-blind study. Safety monitored throughout. Potential ischemic (coronary...
ABSTRACTObjective To assess effects of desvenlafaxine (administered as succinate) on secondary outcomes mood, climacteric symptoms, and treatment satisfaction in postmenopausal women with moderate to severe menopausal vasomotor symptoms (VMS).Methods A 12-week, multicenter, double-blind, placebo-controlled trial was conducted ≥ 50 hot flushes per week. Participants were randomly assigned 100 mg/day, 150 or placebo. Secondary outcome efficacy variables included Profile Mood States (POMS),...
To evaluate the effect of serotonin-norepinephrine re-uptake inhibitor desvenlafaxine on blood pressure and incidence new onset hypertension in pooled short-term studies two longer-term, randomized withdrawal studies.Data from patients randomly assigned to 10 mg 400 mg/day or placebo 11 (8-12 weeks), fixed-dose, double-blind, placebo-controlled major depressive disorder (MDD) were for analysis; (36 46 weeks) analyzed separately.www.clinicaltrials.gov , NCT00072774, NCT00073762, NCT00277823,...
The primary objective of this post-hoc analysis was to evaluate the effect short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients major depressive disorder. Data three randomized, double-blind, placebo-controlled trials 50 or 100 mg/day for disorder were pooled. SD status, determined at baseline and week 8, last observation carried forward. Subgroup analyses addressed effects sex, SD,...
Pregnant and postpartum women have an increased risk of severe complications from COVID-19. Many clinical guidelines recommend vaccination these populations, it is therefore critical to understand their attitudes toward COVID-19 vaccines. We conducted a cross-sectional online survey in November 2020 currently pregnant ≤1-year Brazil, India, the United Kingdom (UK), States (US) that assessed openness vaccines reasons for vaccine hesitancy. Logistic regression analyses were evaluate receiving...
INTRODUCTION: Essure is indicated for women who desire permanent birth control by bilateral fallopian tube occlusion. A confirmation test required 3 months postplacement to evaluate location/retention of inserts. efficacy when an algorithm where TVU used as a first-line option instead modified hysterosalpingogram (HSG) was evaluated in phase 4 study. Patient satisfaction with the reported. METHODS: Women aged 21–44 years and scheduled placement were eligible. At postplacement, participants...